Findings

What do systematic reviews say?

3 questions · 5 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 20%Moderate 1 · 20%High 3 · 60%

Low molecular weight heparin vs active control

Symptomatic VTE · ambulatory cancer patients receiving chemotherapy

Low‐molecular‐weight heparin showed no clear difference in symptomatic VTE compared with with active control (1) (low certainty).

3 findings from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 2.89 [0.12, 66.75]
1 study · 51 participants
Low
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 0.51 [0.22, 1.17]
2 studies · 781 participants
Moderate
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 0.33 [0.14, 0.83]
1 study · 439 participants
High

Low molecular weight heparin vs no thromboprophylaxis

Symptomatic VTE · ambulatory cancer patients receiving chemotherapy

Low‐molecular‐weight heparin leads to lower symptomatic VTE compared with no thromboprophylaxis (high certainty).

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 0.62 [0.46, 0.83]
11 studies · 3931 participants
High

Ultra‐low‐molecular‐weight heparin vs placebo

Symptomatic VTE · ambulatory cancer patients receiving chemotherapy

Ultra‐low‐molecular‐weight heparin leads to lower symptomatic VTE compared with placebo (high certainty).

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 0.36 [0.22, 0.6]
1 study · 3212 participants
High